Samsung Bioepis Aims To Compete On Higher-Strength Humira In US

FDA Accepts sBLA For 100mg/ml Citrate-Free Version Of Hadlima Biosimilar

Samsung Bioepis and Organon have revealed plans to compete with higher-concentration formulations of adalimumab in the US, after the FDA accepted for review an sBLA for a citrate-free 100mg/ml version of the SB5 Hadlima biosimilar that is already approved in a 50mg/ml formulation.

Dial High Black Red
Samsung Bioepis is targeting high-concentration adalimumab • Source: igor kisselev / Alamy Stock Vector

Samsung Bioepis and Organon have revealed plans to compete with higher-concentration formulations of adalimumab in the US, ahead of expected biosimilar market formation in 2023.

So far, only a limited number of developers have pursued Humira biosimilars with a higher-strength 100mg/ml formulation, with most preferring...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.